抗青光眼药物相关眼表疾病的叙述性综述
A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications.
作者信息
Zhou Xiaoyu, Zhang Xinyue, Zhou Dengming, Zhao Yang, Duan Xuanchu
机构信息
Changsha Aier Eye Hospital, Changsha, Hunan Province, China.
The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
出版信息
Ophthalmol Ther. 2022 Oct;11(5):1681-1704. doi: 10.1007/s40123-022-00557-0. Epub 2022 Aug 9.
Abstract
Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injury. Ocular surface diseases damage the ocular microenvironmental health status, reduce the patients' compliance with the treatment, and finally affect the treatment result. Therefore, the ocular surface management of patients with glaucoma is very important. This includes the selection of drugs that are better tolerated according to individual conditions, preservative-free formulations, drugs that protect against ocular surface disease, or selecting surgery and laser treatment, to prevent the damage to the ocular surface by topical anti-glaucomatous drugs.
摘要
局部抗青光眼药物仍然是降低眼压的最重要措施。大量研究证实，长期使用抗青光眼滴眼液，尤其是含有防腐剂苯扎氯铵的滴眼液，可导致或加重眼表损伤。眼表疾病损害眼部微环境健康状况，降低患者治疗依从性，最终影响治疗效果。因此，青光眼患者的眼表管理非常重要。这包括根据个体情况选择耐受性更好的药物、无防腐剂制剂、预防眼表疾病的药物，或选择手术和激光治疗，以防止局部抗青光眼药物对眼表的损害。
相似文献
1
A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications.
Ophthalmol Ther. 2022 Oct;11(5):1681-1704. doi: 10.1007/s40123-022-00557-0. Epub 2022 Aug 9.
2
[Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs].
Zhonghua Yan Ke Za Zhi. 2011 Feb;47(2):101-4.
3
An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Am J Ophthalmol. 2009 Apr;147(4):725-735.e1. doi: 10.1016/j.ajo.2008.10.019. Epub 2009 Feb 1.
4
Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops.
Clin Ophthalmol. 2013;7:2131-5. doi: 10.2147/OPTH.S41358. Epub 2013 Oct 30.
5
[Ocular surface injury resulted from topical anti-glaucoma medications: prevention and cure].
Zhonghua Yan Ke Za Zhi. 2012 Jun;48(6):557-61.
6
The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review.
J Curr Ophthalmol. 2018 Sep 1;31(1):8-15. doi: 10.1016/j.joco.2018.07.003. eCollection 2019 Mar.
7
Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1279-1289. doi: 10.1080/17425255.2016.1209481. Epub 2016 Jul 18.
8
Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
Chin Med J (Engl). 2015 Sep 20;128(18):2444-9. doi: 10.4103/0366-6999.164927.
9
Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.
Adv Ther. 2021 Jun;38(6):3019-3031. doi: 10.1007/s12325-021-01731-9. Epub 2021 Apr 23.
10
Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Optom Vis Sci. 2015 Sep;92(9):e222-6. doi: 10.1097/OPX.0000000000000542.
引用本文的文献
1
Objective Evaluation of Ocular Surface Adverse Effects in Patients Receiving Topical Antiglaucoma Treatment.
Rom J Ophthalmol. 2025 Apr-Jun;69(2):190-199. doi: 10.22336/rjo.2025.31.
2
Short-term effects of antiglaucomatous topical medication on the ocular surface in Wistar rats.
Rom J Ophthalmol. 2025 Apr-Jun;69(2):228-234. doi: 10.22336/rjo.2025.36.
3
Potential benefits of vitamin A and its derivatives in glaucoma.
Eur J Med Res. 2025 Jul 1;30(1):527. doi: 10.1186/s40001-025-02780-4.
4
Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT.
Pharmaceuticals (Basel). 2025 Jun 11;18(6):868. doi: 10.3390/ph18060868.
5
Unraveling the effects of serial intravitreal Aflibercept injections on the ocular surface of patients with glaucoma and retinal comorbidity.
Sci Rep. 2025 Apr 15;15(1):12980. doi: 10.1038/s41598-025-98436-8.
6
Neurotrophic keratopathy: Update in diagnosis and management.
Indian J Ophthalmol. 2025 Apr 1;73(4):483-495. doi: 10.4103/IJO.IJO_2963_24. Epub 2025 Mar 27.
7
Bibliometric and visualized analysis of research hotpots and future prospects in lacrimal duct obstruction disease (1900 to 2024).
Int J Ophthalmol. 2025 Mar 18;18(3):526-540. doi: 10.18240/ijo.2025.03.21. eCollection 2025.
8
Meibomian Gland Loss and Dysfunction in Mild versus Moderate-Severe Thyroid Eye Disease.
J Curr Ophthalmol. 2025 Jan 18;36(2):145-151. doi: 10.4103/joco.joco_176_23. eCollection 2024 Apr-Jun.
9
A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.
Eye (Lond). 2025 Jun;39(8):1599-1607. doi: 10.1038/s41433-025-03646-z. Epub 2025 Feb 25.
10
Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.
Bioengineering (Basel). 2024 Oct 11;11(10):1010. doi: 10.3390/bioengineering11101010.
本文引用的文献
1
Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario.
Indian J Ophthalmol. 2022 Apr;70(4):1163-1170. doi: 10.4103/ijo.IJO_2865_21.
2
Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.
Ann Med. 2022 Dec;54(1):343-358. doi: 10.1080/07853890.2021.1955146.
3
β-blocker eye drops affect ocular surface through β2 adrenoceptor of corneal limbal stem cells.
BMC Ophthalmol. 2021 Dec 5;21(1):419. doi: 10.1186/s12886-021-02186-w.
4
European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition.
Br J Ophthalmol. 2021 Jun;105(Suppl 1):1-169. doi: 10.1136/bjophthalmol-2021-egsguidelines.
5
[Chinese expert consensus on dry eye: dry eye related to drugs (2021)].
Zhonghua Yan Ke Za Zhi. 2021 Oct 11;57(10):734-742. doi: 10.3760/cma.j.cn112142-20210726-00350.
6
Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials.
Graefes Arch Clin Exp Ophthalmol. 2022 Mar;260(3):937-948. doi: 10.1007/s00417-021-05379-7. Epub 2021 Sep 7.
7
Changes in Corneal Epithelial Thickness Induced by Topical Antiglaucoma Medications.
J Clin Med. 2021 Aug 5;10(16):3464. doi: 10.3390/jcm10163464.
8
Glaucoma.
Med Clin North Am. 2021 May;105(3):493-510. doi: 10.1016/j.mcna.2021.01.004. Epub 2021 Apr 2.
9
A 4-week, randomized, double-masked study to evaluate efficacy of deproteinized calf blood extract eye drops versus sodium hyaluronate 0.3% eye drops in dry eye patients with ocular pain.
Ann Palliat Med. 2021 Apr;10(4):3617-3625. doi: 10.21037/apm-20-1453. Epub 2021 Feb 18.
10
Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments.
Clin Ophthalmol. 2020 Oct 30;14:3675-3680. doi: 10.2147/OPTH.S269586. eCollection 2020.
Zotero 插件